• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

BioRelix

edit

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

Milestones

edit

• 
  BioRelix received $269k in Venture Round funding. (4/6/12)
  Posted 4/6/12 at 5:38am via finsmes.com
• 
  BioRelix received $2.56M in Venture Round funding. (3/22/12)
  Posted 3/22/12 at 6:19pm via masshightech.com
• 
  BioRelix received $25.8M in Series A funding. (6/11/07)
  Posted 3/22/12 at 6:18pm via masshightech.com
• 
  BioRelix received $500k in Venture Round funding. (1/18/12)
  Posted 1/18/12 at 6:54pm via masshightech.com
• 
  BioRelix received $3.6M in Venture Round funding. (9/6/11)
  Posted 9/6/11 at 6:42pm via masshightech.com
• 
  BioRelix received $2.4M in Debt funding. (12/23/10)
  Posted 12/23/10 at 9:07pm via masshightech.com

Videos

Screenshots

edit

Sources

1. Nutmeg State biotech lands $25.8M in round one (masshightech.com) [edit]
2. BioRelix lands $2.4M financing (masshightech.com) [edit]
3. BioRelix lands $3.6M to treat infectious diseases (masshightech.com) [edit]
4. Conn. antibiotics maker BioRelix rounds up $500K (masshightech.com) [edit]
5. Connecticut biotech raises $2.56M round (masshightech.com) [edit]
6. BioRelix Receives $269K Follow-on Investment from Connecticut Innovations (finsmes.com) [edit]